153 related articles for article (PubMed ID: 17063617)
21. Flt3 ligand promotes myeloid dendritic cell differentiation of human hematopoietic progenitor cells: possible application for cancer immunotherapy.
Harada S; Kimura T; Fujiki H; Nakagawa H; Ueda Y; Itoh T; Yamagishi H; Sonoda Y
Int J Oncol; 2007 Jun; 30(6):1461-8. PubMed ID: 17487367
[TBL] [Abstract][Full Text] [Related]
22. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma.
Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA
J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012
[TBL] [Abstract][Full Text] [Related]
23. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.
Burch PA; Breen JK; Buckner JC; Gastineau DA; Kaur JA; Laus RL; Padley DJ; Peshwa MV; Pitot HC; Richardson RL; Smits BJ; Sopapan P; Strang G; Valone FH; Vuk-Pavlović S
Clin Cancer Res; 2000 Jun; 6(6):2175-82. PubMed ID: 10873066
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
25. Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy.
Berhanu A; Huang J; Alber SM; Watkins SC; Storkus WJ
Cancer Res; 2006 May; 66(9):4895-903. PubMed ID: 16651446
[TBL] [Abstract][Full Text] [Related]
26. Dendritic cells and their role in cancer immunotherapy.
Jalili A
Iran J Immunol; 2007 Sep; 4(3):127-44. PubMed ID: 17767012
[TBL] [Abstract][Full Text] [Related]
27. Antigen presentation by dendritic cells and their significance in antineoplastic immunotherapy.
Bodey B; Siegel SE; Kaiser HE
In Vivo; 2004; 18(1):81-100. PubMed ID: 15011756
[TBL] [Abstract][Full Text] [Related]
28. Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine.
Yo YT; Hsu KF; Shieh GS; Lo CW; Chang CC; Wu CL; Shiau AL
Cancer Gene Ther; 2007 Nov; 14(11):904-17. PubMed ID: 17704754
[TBL] [Abstract][Full Text] [Related]
29. A dendritic cell population generated by a fusion of GM-CSF and IL-21 induces tumor-antigen-specific immunity.
Williams P; Bouchentouf M; Rafei M; Romieu-Mourez R; Hsieh J; Boivin MN; Yuan S; Forner KA; Birman E; Galipeau J
J Immunol; 2010 Dec; 185(12):7358-66. PubMed ID: 21076067
[TBL] [Abstract][Full Text] [Related]
30. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies.
Dela Cruz JS; Trinh KR; Chen HW; Ribas A; Morrison SL; Penichet ML
Mol Immunol; 2006 Feb; 43(6):667-76. PubMed ID: 15908002
[TBL] [Abstract][Full Text] [Related]
31. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
32. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer.
Simons JW; Sacks N
Urol Oncol; 2006; 24(5):419-24. PubMed ID: 16962494
[TBL] [Abstract][Full Text] [Related]
33. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
[TBL] [Abstract][Full Text] [Related]
34. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies.
Klippstein R; Pozo D
Nanomedicine; 2010 Aug; 6(4):523-9. PubMed ID: 20085824
[TBL] [Abstract][Full Text] [Related]
35. Cytokines in the generation and maturation of dendritic cells: recent advances.
Zou GM; Tam YK
Eur Cytokine Netw; 2002; 13(2):186-99. PubMed ID: 12101074
[TBL] [Abstract][Full Text] [Related]
36. [In vitro inducing differentiation of bone marrow mononuclear cells of chronic myeloid leukemia].
Wu CY; Zhang LS; Zhang YF; Chai Y; Yi LC; Song FX
Ai Zheng; 2005 Apr; 24(4):425-31. PubMed ID: 15820064
[TBL] [Abstract][Full Text] [Related]
37. Recent progress in GM-CSF-based cancer immunotherapy.
Yan WL; Shen KY; Tien CY; Chen YA; Liu SJ
Immunotherapy; 2017 Mar; 9(4):347-360. PubMed ID: 28303764
[TBL] [Abstract][Full Text] [Related]
38. Dendritic cells and cytokines in immune rejection of cancer.
Ferrantini M; Capone I; Belardelli F
Cytokine Growth Factor Rev; 2008 Feb; 19(1):93-107. PubMed ID: 18054517
[TBL] [Abstract][Full Text] [Related]
39. Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types.
Hong IS
Exp Mol Med; 2016 Jul; 48(7):e242. PubMed ID: 27364892
[TBL] [Abstract][Full Text] [Related]
40. A dendritic cell primer for oncology nurses.
DeMeyer ES; Buchsel PC
Clin J Oncol Nurs; 2005 Aug; 9(4):460-4. PubMed ID: 16117213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
